Although urate-lowering therapies—such as xanthine oxidase inhibitors—have traditionally been used to manage gout, they may offer additional metabolic benefits in patients with hyperuricemia and insulin resistance, potentially aiding in the prevention of type 2 diabetes and its cardiometabolic complications. This evidence concerns the gene XDH and Insulin resistance.